IL153236A0 - The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders - Google Patents
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disordersInfo
- Publication number
- IL153236A0 IL153236A0 IL15323601A IL15323601A IL153236A0 IL 153236 A0 IL153236 A0 IL 153236A0 IL 15323601 A IL15323601 A IL 15323601A IL 15323601 A IL15323601 A IL 15323601A IL 153236 A0 IL153236 A0 IL 153236A0
- Authority
- IL
- Israel
- Prior art keywords
- copolymer
- treatment
- nervous system
- central nervous
- system disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58752300A | 2000-06-05 | 2000-06-05 | |
PCT/US2001/018248 WO2001093828A1 (en) | 2000-06-05 | 2001-06-05 | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153236A0 true IL153236A0 (en) | 2003-07-06 |
Family
ID=24350145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15323601A IL153236A0 (en) | 2000-06-05 | 2001-06-05 | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1292279A4 (en) |
JP (1) | JP2003535118A (en) |
AU (2) | AU2001275280B2 (en) |
CA (1) | CA2411536A1 (en) |
HU (1) | HUP0302333A3 (en) |
IL (1) | IL153236A0 (en) |
PL (1) | PL363431A1 (en) |
WO (1) | WO2001093828A1 (en) |
ZA (1) | ZA200210084B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
ES2527760T3 (en) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Treatment of Crohn's disease with copolymer 1 and polypeptides |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
AU2002353059B2 (en) | 2001-12-04 | 2008-06-19 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
DK1797109T3 (en) | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
LT2630962T (en) | 2009-08-20 | 2018-10-25 | Yeda Research & Development Company, Ltd. | Low Frequency Glatiramer Acetate Therapy |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
ES2602977T3 (en) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as biomarkers predictive of the clinical response for glatiramer acetate |
JP2014530819A (en) | 2011-10-10 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | Single nucleotide polymorphisms useful for predicting clinical responsiveness to glatiramer acetate |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
UY35790A (en) | 2013-10-21 | 2015-05-29 | Teva Pharma | GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE |
DK3185882T3 (en) | 2014-08-29 | 2020-01-27 | Region Midtjylland | Positively charged copolymers for use as antimicrobial agents |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
CN106924175B (en) * | 2015-12-29 | 2020-07-03 | 深圳翰宇药业股份有限公司 | Pharmaceutical composition for treating multiple sclerosis |
EP3458036B1 (en) * | 2016-05-20 | 2023-08-23 | Cedars-Sinai Medical Center | Treating or preventing alzheimer's disease and associated conditions |
CN110382052A (en) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | The copaxone store system of multiple sclerosis for therapeutic advance type form |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
GB9411292D0 (en) * | 1994-06-06 | 1994-07-27 | Teva Pharma | Pharmaceuticals compositions |
US5665764A (en) * | 1995-06-02 | 1997-09-09 | Warner-Lambert Company | Tricyclic inhibitors of matrix metalloproteinases |
IL119989A0 (en) * | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
WO2001052878A2 (en) * | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
NZ520282A (en) * | 2000-06-07 | 2004-09-24 | Yeda Res & Dev | The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
-
2001
- 2001-06-05 PL PL01363431A patent/PL363431A1/en not_active Application Discontinuation
- 2001-06-05 AU AU2001275280A patent/AU2001275280B2/en not_active Ceased
- 2001-06-05 AU AU7528001A patent/AU7528001A/en active Pending
- 2001-06-05 IL IL15323601A patent/IL153236A0/en unknown
- 2001-06-05 JP JP2002501401A patent/JP2003535118A/en active Pending
- 2001-06-05 WO PCT/US2001/018248 patent/WO2001093828A1/en not_active Application Discontinuation
- 2001-06-05 EP EP01941973A patent/EP1292279A4/en not_active Withdrawn
- 2001-06-05 CA CA002411536A patent/CA2411536A1/en not_active Abandoned
- 2001-06-05 HU HU0302333A patent/HUP0302333A3/en unknown
-
2002
- 2002-12-12 ZA ZA200210084A patent/ZA200210084B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU7528001A (en) | 2001-12-17 |
PL363431A1 (en) | 2004-11-15 |
AU2001275280B2 (en) | 2006-03-16 |
CA2411536A1 (en) | 2001-12-13 |
HUP0302333A2 (en) | 2003-11-28 |
EP1292279A1 (en) | 2003-03-19 |
HUP0302333A3 (en) | 2005-07-28 |
JP2003535118A (en) | 2003-11-25 |
EP1292279A4 (en) | 2005-01-12 |
ZA200210084B (en) | 2003-12-12 |
WO2001093828A1 (en) | 2001-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7528001A (en) | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders | |
HUP0100069A3 (en) | 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders | |
HUP0004439A3 (en) | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders | |
HK1046274A1 (en) | Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders. | |
AU9112201A (en) | Pulmonary delivery in treating disorders of the central nervous system | |
HUP0100786A3 (en) | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | |
IL151946A0 (en) | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders | |
HUP0401023A3 (en) | Use of flibanserin in the treatment of sexual disorders | |
EP0924983A4 (en) | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders | |
AU2001266152A1 (en) | Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them | |
IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
ZA97741B (en) | Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders. | |
AU2001256855A1 (en) | Preparation for the prevention and treatment of ocular disorders | |
IL150289A0 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
IL160018A0 (en) | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | |
EP1079764A4 (en) | The treatment of sexual dysfunction in certain patient groups | |
GB0015228D0 (en) | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders | |
HUP0301553A3 (en) | Pharmaceutical compositions and their use for treating neurological disorders | |
AU2002226060A1 (en) | Compositions containing gangliosides for use in the treatment of skin disorders | |
IL129460A0 (en) | Use of lofexidine in the treatment of behavioral disorders | |
AU5963396A (en) | Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders | |
AU2002210763A1 (en) | Use of 1-ebio in the treatment of bipolar disorders | |
AU6330300A (en) | Use of interleukin-6 in treatment of obesity and/or obesity associated disorders | |
AU2001292500A1 (en) | 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain | |
HUP0200552A2 (en) | Use of apoptosis inducing agents in the treatment of (auto)immune diseases |